Roth Capital Has Bullish Forecast for NAGE FY2025 Earnings

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Analysts at Roth Capital lifted their FY2025 earnings estimates for Niagen Bioscience in a research report issued to clients and investors on Wednesday, November 5th. Roth Capital analyst S. Mcgowan now expects that the company will earn $0.17 per share for the year, up from their previous estimate of $0.08. Roth Capital also issued estimates for Niagen Bioscience’s Q1 2026 earnings at $0.05 EPS, Q3 2026 earnings at $0.07 EPS, FY2026 earnings at $0.23 EPS, Q3 2027 earnings at $0.14 EPS and FY2027 earnings at $0.46 EPS.

A number of other research firms have also commented on NAGE. Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research report on Wednesday, October 8th. Canaccord Genuity Group lowered their target price on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday. Wall Street Zen downgraded shares of Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. Finally, HC Wainwright increased their price objective on shares of Niagen Bioscience from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, August 11th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.28.

Niagen Bioscience Stock Up 3.6%

NAGE stock opened at $6.84 on Friday. The firm has a market capitalization of $545.51 million, a PE ratio of 32.57 and a beta of 2.16. Niagen Bioscience has a twelve month low of $5.16 and a twelve month high of $14.69. The stock’s 50 day moving average is $8.35 and its 200-day moving average is $9.73.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The firm had revenue of $33.99 million during the quarter, compared to analysts’ expectations of $31.30 million.

Hedge Funds Weigh In On Niagen Bioscience

Several large investors have recently modified their holdings of the business. Hussman Strategic Advisors Inc. bought a new stake in Niagen Bioscience during the 3rd quarter valued at $980,000. SG Americas Securities LLC bought a new position in Niagen Bioscience in the 3rd quarter valued at $482,000. State of Alaska Department of Revenue purchased a new position in shares of Niagen Bioscience during the 3rd quarter valued at $44,000. KLP Kapitalforvaltning AS bought a new position in shares of Niagen Bioscience in the third quarter worth $107,000. Finally, D.A. Davidson & CO. bought a new position in shares of Niagen Bioscience in the third quarter worth $251,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.